Resource impact statement
No significant resource impact is anticipated
NICE has recommended upadacitinib alone or in combination with methotrexate, as an option for treating active rheumatoid arthritis in adults in accordance with the criteria specified in the guidance. Please see the guidance for further details.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).
This is because the technology is a further treatment option and is available at a similar price to the current treatment options.
Upadacitinib has a discount that is commercial in confidence. For enquiries about the patient access scheme, please contact pricing@abbvie.com
A resource impact template is provided for completion at a local level. This is because there are numerous treatment options that are recommended by NICE for severe rheumatoid arthritis. The local template updates previous NICE resource impact tools for severe rheumatoid arthritis.
Upadacitinib is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.
This page was last updated: